15.97
+0.02(+0.13%)
Currency In USD
| Previous Close | 15.95 |
| Open | 15.93 |
| Day High | 16.04 |
| Day Low | 15.62 |
| 52-Week High | 35.84 |
| 52-Week Low | 15.45 |
| Volume | 408,593 |
| Average Volume | 453,111 |
| Market Cap | 461.09M |
| PE | -84.05 |
| EPS | -0.19 |
| Moving Average 50 Days | 18.81 |
| Moving Average 200 Days | 26.01 |
| Change | 0.02 |
If you invested $1000 in Castle Biosciences, Inc. (CSTL) since IPO date, it would be worth $746.26 as of June 01, 2025 at a share price of $15.97. Whereas If you bought $1000 worth of Castle Biosciences, Inc. (CSTL) shares 5 years ago, it would be worth $413.73 as of June 01, 2025 at a share price of $15.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes
GlobeNewswire Inc.
May 29, 2025 8:30 PM GMT
Study results show that DecisionDx-Melanoma was associated with a 32% reduction in mortality risk compared to untested patientsFRIENDSWOOD, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 21, 2025 11:00 AM GMT
FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a compa
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
GlobeNewswire Inc.
May 09, 2025 11:00 AM GMT
FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recentl